SUBSCRIBE
SUBSCRIBE
News   Deals

Bristol-Myers Squibb Company Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of KOSAN Biosciences, Inc.

June 18, 2008 | 
1 min read

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino review period for its tender offer for Kosan Biosciences Incorporated (NASDAQ: KOSN) (“Kosan”) has expired.

Mergers & acquisitions
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Illustration of two arrows merging into one
Mergers & acquisitions
Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
March 13, 2025
 · 
2 min read
 · 
Tristan Manalac
Concept of money prize. Vector illustration. Halftone hand holds bouquet of money flowers. Gift prize, donation, earnings, bonus or cashback concept. Retro poster or banner. Creative trend collage.
Weight loss
Roche Makes Another Obesity Play With Potential $5.3B Amylin Pact With Zealand
March 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Hands in black and white dropping a collection of pills on a pink background
Manufacturing
Viking Secures 1B Supply of Obesity Pill Candidate With $150M Prepayment Deal
March 11, 2025
 · 
2 min read
 · 
Annalee Armstrong
Trendy halftone collage. Concept of contracting, negotiation, contracting, favorable terms. Trendy modern retro illustration on business theme. Concept of teamwork. Vector illustration
Mergers & acquisitions
BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement
March 11, 2025
 · 
3 min read
 · 
Tristan Manalac